Zheng Ma, Ge Cui, Lijie Dou, Fangfang Chen, Prof. Dr. Hexin Xie
{"title":"2-羧基喹啉硼酸作为高效KPC抑制剂。","authors":"Zheng Ma, Ge Cui, Lijie Dou, Fangfang Chen, Prof. Dr. Hexin Xie","doi":"10.1002/cmdc.202400901","DOIUrl":null,"url":null,"abstract":"<p>The expression of <i>Klebsiella pneumoniae</i> carbapenemase (KPC), a type of carbapenem-hydrolyzing β-lactamase, in Gram-negative bacteria has caused significant bacterial resistance to carbapenems, the antibiotic of last resort. Herein, we describe the discovery of 2-carboxyquinoline boronic acids as inhibitor of KPC. We have identified fluoro-substituted carboxyquinoline boronic acids <b>1 e</b> as the most potent inhibitor, with an IC<sub>50</sub> of 8.3 nM for KPC-2, while this compound is significantly less efficient at reducing the activity of other β-lactamases. This compound proved to have low cytotoxicity towards mammalian cells, as well as low haemolysis and antibacterial activity. However, <b>1 e</b> potentiated the efficacy of β-lactam antibiotics (e. g., meropenem and ceftazidime) against KPC-2-expressing resistant <i>Klebsiella pneumonia</i> by up to 256-fold.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"20 7","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2-Carboxyquinoline Boronic Acids as Highly Potent KPC Inhibitors\",\"authors\":\"Zheng Ma, Ge Cui, Lijie Dou, Fangfang Chen, Prof. Dr. Hexin Xie\",\"doi\":\"10.1002/cmdc.202400901\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The expression of <i>Klebsiella pneumoniae</i> carbapenemase (KPC), a type of carbapenem-hydrolyzing β-lactamase, in Gram-negative bacteria has caused significant bacterial resistance to carbapenems, the antibiotic of last resort. Herein, we describe the discovery of 2-carboxyquinoline boronic acids as inhibitor of KPC. We have identified fluoro-substituted carboxyquinoline boronic acids <b>1 e</b> as the most potent inhibitor, with an IC<sub>50</sub> of 8.3 nM for KPC-2, while this compound is significantly less efficient at reducing the activity of other β-lactamases. This compound proved to have low cytotoxicity towards mammalian cells, as well as low haemolysis and antibacterial activity. However, <b>1 e</b> potentiated the efficacy of β-lactam antibiotics (e. g., meropenem and ceftazidime) against KPC-2-expressing resistant <i>Klebsiella pneumonia</i> by up to 256-fold.</p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\"20 7\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-12-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202400901\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202400901","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
2-Carboxyquinoline Boronic Acids as Highly Potent KPC Inhibitors
The expression of Klebsiella pneumoniae carbapenemase (KPC), a type of carbapenem-hydrolyzing β-lactamase, in Gram-negative bacteria has caused significant bacterial resistance to carbapenems, the antibiotic of last resort. Herein, we describe the discovery of 2-carboxyquinoline boronic acids as inhibitor of KPC. We have identified fluoro-substituted carboxyquinoline boronic acids 1 e as the most potent inhibitor, with an IC50 of 8.3 nM for KPC-2, while this compound is significantly less efficient at reducing the activity of other β-lactamases. This compound proved to have low cytotoxicity towards mammalian cells, as well as low haemolysis and antibacterial activity. However, 1 e potentiated the efficacy of β-lactam antibiotics (e. g., meropenem and ceftazidime) against KPC-2-expressing resistant Klebsiella pneumonia by up to 256-fold.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.